Audentes Therapeutics to Present at the 2016 Wedbush PacGrow Healthcare Conference

SAN FRANCISCO, Calif., Aug. 8, 2016 /PRNewswire/ -- Audentes Therapeutics, Inc. (Nasdaq: BOLD), a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening diseases, today announced that Matthew R. Patterson, President and Chief Executive Officer, will present at the 2016 Wedbush PacGrow Healthcare Conference on Wednesday, August 17, 2016 at 10:20 am ET.

To access the live webcast of the Audentes presentation, please visit the Events & Presentations page within the Investors & News section of the Audentes website. Replays of the webcast will be available on the Audentes website for approximately 30 days following the conference.

About Audentes Therapeutics, Inc.
Audentes Therapeutics is a biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening diseases.  We have four products in development, AT132 for the treatment of X-Linked Myotubular Myopathy (XLMTM), AT342 for the treatment of Crigler-Najjar Syndrome, AT982 for the treatment of Pompe disease and AT307 for the treatment of the CASQ2 subtype of Catecholaminergic Polymorphic Ventricular Tachycardia (CASQ2-CPVT).  We are a focused, experienced and passionate team committed to forging strong, global relationships with the patient, research and medical communities.

For more information regarding Audentes, please visit www.audentestx.com.

Audentes Contacts:

Investor Contact:
Thomas Soloway, CFO
415.818.1040
[email protected]

Media Contact:
Jeffrey Gruis
415.818.1015
[email protected]

Logo - http://photos.prnewswire.com/prnh/20160719/391266LOGO

SOURCE Audentes Therapeutics, Inc.

Related Links

http://audentestx.com